Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 10, 2022

SELL
$9.93 - $15.39 $2.86 Million - $4.44 Million
-288,484 Closed
0 $0
Q2 2021

Jul 20, 2021

BUY
$18.57 - $35.68 $1.93 Million - $3.71 Million
103,859 Added 56.25%
288,484 $7.68 Million
Q4 2020

Jan 22, 2021

SELL
$37.09 - $48.97 $2.54 Million - $3.35 Million
-68,416 Reduced 27.04%
184,625 $6.85 Million
Q3 2020

Oct 19, 2020

BUY
$40.47 - $45.5 $1.58 Million - $1.78 Million
39,141 Added 18.3%
253,041 $10.4 Million
Q2 2020

Jul 23, 2020

SELL
$32.57 - $42.83 $569,975 - $749,525
-17,500 Reduced 7.56%
213,900 $8.67 Million
Q4 2019

Jan 21, 2020

SELL
$34.58 - $48.06 $8.87 Million - $12.3 Million
-256,500 Reduced 52.57%
231,400 $10,000
Q3 2019

Oct 21, 2019

BUY
$36.98 - $48.45 $16.2 Million - $21.2 Million
436,900 Added 856.67%
487,900 $18,000
Q2 2019

Aug 01, 2019

SELL
$35.13 - $55.53 $8.43 Million - $13.3 Million
-239,900 Reduced 82.47%
51,000 $2.29 Million
Q1 2019

May 02, 2019

SELL
$42.83 - $59.91 $2.57 Million - $3.59 Million
-60,000 Reduced 17.1%
290,900 $15.8 Million
Q4 2018

Feb 14, 2019

SELL
$37.97 - $60.16 $2.28 Million - $3.61 Million
-60,000 Reduced 14.6%
350,900 $16.2 Million
Q3 2018

Nov 07, 2018

BUY
$56.3 - $67.25 $12.5 Million - $15 Million
222,800 Added 118.45%
410,900 $25 Million
Q2 2018

Aug 14, 2018

BUY
$44.9 - $64.95 $1.55 Million - $2.25 Million
34,600 Added 22.54%
188,100 $11.8 Million
Q1 2018

May 09, 2018

SELL
$45.35 - $61.65 $453,500 - $616,500
-10,000 Reduced 6.12%
153,500 $7.09 Million
Q4 2017

Feb 07, 2018

SELL
$41.95 - $60.1 $3.57 Million - $5.11 Million
-85,000 Reduced 34.21%
163,500 $7.75 Million
Q3 2017

Nov 03, 2017

BUY
$33.4 - $53.9 $8.3 Million - $13.4 Million
248,500
248,500 $13.4 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $34.7M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.